18F-FDG-PET/CT analysis in hospitalized patients affected by pulmonary disease: The experience of the Nuclear Medicine Unit of "Policlinico Tor Vegata".
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Oct 2021
01 Oct 2021
Historique:
entrez:
16
9
2021
pubmed:
17
9
2021
medline:
21
1
2022
Statut:
ppublish
Résumé
The main aim of this study was to retrospectively evaluate the clinical data and outcomes of a cohort of 492 hospitalized patients who underwent fluorine-18-fluorodeoxyglucose (F-FDG)-PET/CT analysis at the nuclear medicine unit of 'Policlinico Tor Vergata' in Rome during the years 2017 and 2018 with particular emphasis for patients affected by pulmonary diseases. Anamnestic data (age and gender), main pathologic conditions, results of F-FDG-PET/CT examination, appropriateness of the request, and medical records of 492 consecutive hospitalized patients who underwent F-FDG-PET/CT analysis (55.38 ± 3.78 years; range 33-81 years) from January 2017 to December 2018 were obtained. Considering all examinations, positive results were observed in 66.9% of cases whereas it was not possible to perform a diagnosis in 12.7% of cases (doubt results). About 20-fold increase in the percentage of doubt results was observed in F-FDG-PET/CT analysis with no appropriateness as compared to those with double appropriateness (both the request and clinical). Noteworthy, our data showed a 95% higher concordance between the positive results of the F-FDG-PET/CT examination and the histologic diagnosis. Conversely, the concordance between the analysis of the bronchoalveolar lavages and the PET analysis was very low. Data here reported showed the high accuracy of the F-FDG-PET/CT performed in our department, mainly for pulmonary diseases, also highlighting the importance of continuously updating the selection criteria for patients who need PET examinations.
Identifiants
pubmed: 34528930
doi: 10.1097/MNM.0000000000001444
pii: 00006231-202110000-00006
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1104-1111Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Quartuccio N, Evangelista L, Alongi P, Caobelli F, Altini C, Cistaro A, et al.; Young AIMN Working Group. Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study. Nucl Med Commun. 2019; 40:808–814.
Schillaci O. Use of dual-point fluorodeoxyglucose imaging to enhance sensitivity and specificity. Semin Nucl Med. 2012; 42:267–280.
Schillaci O, Spanu A, Madeddu G. [99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors. Q J Nucl Med Mol Imaging. 2005; 49:133–144.
El-Galaly TC, Gormsen LC, Hutchings M. PET/CT for staging; past, present, and future. Semin Nucl Med. 2018; 48:4–16.
Tan H, Gu Y, Yu H, Hu P, Zhang Y, Mao W, Shi H. Total-body PET/CT: current applications and future perspectives. AJR Am J Roentgenol. 2020; 215:325–337.
van Loon J, Grutters JP, Wanders R, Boersma L, Dingemans AM, Bootsma G, et al. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation. Eur J Cancer. 2010; 46:110–119.
Alesawi HM, Yakar D, Glaudemans AWJM, Kwee TC. Frequency, determinants, and costs of recommendations for additional imaging in clinical 18F-FDG PET/CT reports. J Nucl Med. 2019; 60:1228–1233.
Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996; 23:737–743.
Caetano R, Schluckebier LF, Bastos CR, Silva RM, Carneiro MP, Silva JW, et al. Análise dos custos do procedimento PET-TC com 18 F-FDG na perspectiva do SUS provedor: estudo em uma unidade pública de saúde do Rio de Janeiro, Brasil [Cost analysis of18F-FDG PET-CT from the perspective of the Brazilian Unified National Health System as healthcare provider: a study in a public healthcare center in Rio de Janeiro, Brazil]. Cad Saude Publica. 2014; 30:379–392. Portuguese.
Jadvar H, Colletti PM, Delgado-Bolton R, Esposito G, Krause BJ, Iagaru AH, et al. Appropriate Use Criteria for 18F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. J Nucl Med. 2017; 58:2026–2037.
Palumbo B, Buresta T, Nuvoli S, Spanu A, Schillaci O, Fravolini ML, Palumbo I. SPECT and PET serve as molecular imaging techniques and in vivo biomarkers for brain metastases. Int J Mol Sci. 2014; 15:9878–9893.
Wright CL, Binzel K, Zhang J, Knopp MV. Advanced functional tumor imaging and precision nuclear medicine enabled by Digital PET Technologies. Contrast Media Mol Imaging. 2017; 2017:5260305.
Urbano N, Scimeca M, Bonanno E, Schillaci O. Nuclear medicine and anatomic pathology in personalized medicine: a challenging alliance. Per Med. 2018; 15:457–459.
Vaidyanathan S, Patel CN, Scarsbrook AF, Chowdhury FU. FDG PET/CT in infection and inflammation–current and emerging clinical applications. Clin Radiol. 2015; 70:787–800.
Rahman WT, Wale DJ, Viglianti BL, Townsend DM, Manganaro MS, Gross MD, et al. The impact of infection and inflammation in oncologic 18F-FDG PET/CT imaging. Biomed Pharmacother. 2019; 117:109168.
Corrales-Medina VF, Habibi CM, Wang J, Glassman SJ, MacPherson P, Beanlands RS, et al. A novel method to measure vascular inflammation by [18F]fluorodeoxyglucose PET/computed tomography scanning of the aorta. Nucl Med Commun. 2019; 40:1087–1089.
Bashir U, Foot O, Wise O, Siddique MM, Mclean E, Bille A, et al. Investigating the histopathologic correlates of 18F-FDG PET heterogeneity in non-small-cell lung cancer. Nucl Med Commun. 2018; 39:1197–1206.
Agarwal H, Singh L, Sengar M. Infantile digital fibromatosis: clues and pitfalls for cytological diagnosis. Cytopathology. 2019; 30:565–566.
Crumley S, Hull A, Cernoch P, Mody D, Sneige N. Comparison between cytologic examination of fungi in bronchial washings and bronchoalveolar lavage specimens and culture: a review of 100 cases with emphasis on diagnostic pitfalls. J Am Soc Cytopathol. 2014; 3:211–217.
Scimeca M, Urbano N, Bonfiglio R, Schillaci O, Bonanno E. Management of oncological patients in the digital era: anatomic pathology and nuclear medicine teamwork. Future Oncol. 2018; 14:1013–1015.
Urbano N, Scimeca M, Bonfiglio R, Bonanno E, Schillaci O. New advance in breast cancer pathology and imaging. Future Oncol. 2019; 15:2707–2722.
Schillaci O, Scimeca M, Toschi N, Bonfiglio R, Urbano N, Bonanno E. Combining diagnostic imaging and pathology for improving diagnosis and prognosis of cancer. Contrast Media Mol Imaging. 2019; 2019:9429761.
Tian M, He X, Jin C, He X, Wu S, Zhou R, et al. Transpathology: molecular imaging-based pathology. Eur J Nucl Med Mol Imaging. 2021. doi: 10.1007/s00259-021-05234-1. [Epub ahead of print]
doi: 10.1007/s00259-021-05234-1